Skip to main content
Erschienen in: AIDS and Behavior 7/2016

21.03.2016 | Original Paper

Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.

verfasst von: Jeffrey T. Parsons, H. Jonathon Rendina, Thomas H. F. Whitfield, Christian Grov

Erschienen in: AIDS and Behavior | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

We sought to determine preferences for oral versus long-acting injectable (LAI) PrEP among gay and bisexual men (GBM). We surveyed a national U.S. sample of 1071 GBM about forms of PrEP. LAI PrEP was found to be acceptable among 43.2 % of men when injected monthly compared with 53.6 % of men when injected every 3 months. When asked to choose between forms of PrEP, 46.0 % preferred LAI, 14.3 % oral, 21.7 % whichever was most effective, 10.1 % had no preference, and 7.8 % would not take PrEP. There were no differences in PrEP preferences by race/ethnicity, income, region of residence, or relationship status. Those unwilling to take PrEP were significantly older than those who preferred LAI PrEP and those who would take either. Those who preferred the most effective form were younger, had less education, and reported more recent club drug use. Those who reported condomless anal sex and those who thought they were good PrEP candidates were more willing to take PrEP. Long-term health and side effects were of the greatest concern for both LAI and oral PrEP. The availability of LAI PrEP has the potential to increase uptake among GBM. The results of ongoing clinical trials of LAI PrEP will need to demonstrate similar or greater efficacy as daily Truvada for uptake to be maximized.
Literatur
1.
Zurück zum Zitat CDC. Estimated HIV incidence in the United States, 2007–2010. HIV surveillance supplemental report. 2012;17(4). CDC. Estimated HIV incidence in the United States, 2007–2010. HIV surveillance supplemental report. 2012;17(4).
6.
Zurück zum Zitat Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.CrossRefPubMed
8.
Zurück zum Zitat Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
9.
Zurück zum Zitat Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, et al. Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya. AIDS Behav. 2015;19(5):794–801.CrossRefPubMed Mugo PM, Sanders EJ, Mutua G, van der Elst E, Anzala O, Barin B, et al. Understanding adherence to daily and intermittent regimens of oral HIV pre-exposure prophylaxis among men who have sex with men in Kenya. AIDS Behav. 2015;19(5):794–801.CrossRefPubMed
11.
12.
Zurück zum Zitat Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefPubMedPubMedCentral Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–22.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Molina J, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, et al., editors. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on retroviruses and opportunistic infections; 2015. Molina J, Capitant C, Spire B, Pialoux G, Chidiac C, Charreau I, et al., editors. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial. Conference on retroviruses and opportunistic infections; 2015.
14.
Zurück zum Zitat Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.CrossRefPubMedPubMedCentral Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, et al. High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav. 2013;17(6):2162–72.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013;8(9):e74314.CrossRefPubMedPubMedCentral Kibengo FM, Ruzagira E, Katende D, Bwanika AN, Bahemuka U, Haberer JE, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS One. 2013;8(9):e74314.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Parsons JT, Rendina HJ, Grov C, Ventuneac A, Mustanski B. Accuracy of highly sexually active gay and bisexual men’s predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis. JAIDS J Acquir Immun Defic Syndr. 2015;68(4):449–55.CrossRef Parsons JT, Rendina HJ, Grov C, Ventuneac A, Mustanski B. Accuracy of highly sexually active gay and bisexual men’s predictions of their daily likelihood of anal sex and its relevance for intermittent event-driven HIV pre-exposure prophylaxis. JAIDS J Acquir Immun Defic Syndr. 2015;68(4):449–55.CrossRef
17.
Zurück zum Zitat Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. Lancet. 2014;383(9915):399–400.CrossRefPubMed Kirby T, Thornber-Dunwell M. Uptake of PrEP for HIV slow among MSM. Lancet. 2014;383(9915):399–400.CrossRefPubMed
18.
Zurück zum Zitat Mayer KH, Hosek S, Cohen S, Liu A, Pickett J, Warren M, et al. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc. 2015;18(4Suppl 3):19980.PubMedPubMedCentral Mayer KH, Hosek S, Cohen S, Liu A, Pickett J, Warren M, et al. Antiretroviral pre-exposure prophylaxis implementation in the United States: a work in progress. J Int AIDS Soc. 2015;18(4Suppl 3):19980.PubMedPubMedCentral
19.
Zurück zum Zitat Mayer KH, Levine K, Grasso C, Krakower D, Mimiaga MJ, editors. Recent increases in PrEP utilization at a Boston Community Health Center among men who have sex with men, 2011–2014: transition from research to clinical practice. Conference on retroviruses and opportunistic infections (CROI), Seattle; 2015. Mayer KH, Levine K, Grasso C, Krakower D, Mimiaga MJ, editors. Recent increases in PrEP utilization at a Boston Community Health Center among men who have sex with men, 2011–2014: transition from research to clinical practice. Conference on retroviruses and opportunistic infections (CROI), Seattle; 2015.
20.
Zurück zum Zitat Grov C, Whitfield TH, Rendina HJ, Ventuneac A, Parsons JT. Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav. 2015;19:1–11.CrossRef Grov C, Whitfield TH, Rendina HJ, Ventuneac A, Parsons JT. Willingness to take PrEP and potential for risk compensation among highly sexually active gay and bisexual men. AIDS Behav. 2015;19:1–11.CrossRef
21.
Zurück zum Zitat Krakower DS, Mayer KH. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs. 2015;75(3):243–51.CrossRefPubMedPubMedCentral Krakower DS, Mayer KH. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Drugs. 2015;75(3):243–51.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8(12):e81997.CrossRefPubMedPubMedCentral Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One. 2013;8(12):e81997.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Pérez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of PrEP uptake among racially/ethnically diverse young men who have sex with men: the P18 study. AIDS Educ Prev. 2015;27(2):112–25.CrossRefPubMedPubMedCentral Pérez-Figueroa RE, Kapadia F, Barton SC, Eddy JA, Halkitis PN. Acceptability of PrEP uptake among racially/ethnically diverse young men who have sex with men: the P18 study. AIDS Educ Prev. 2015;27(2):112–25.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT Health. 2014;1:1–7.CrossRef Gallagher T, Link L, Ramos M, Bottger E, Aberg J, Daskalakis D. Self-perception of HIV risk and candidacy for pre-exposure prophylaxis among men who have sex with men testing for HIV at commercial sex venues in New York City. LGBT Health. 2014;1:1–7.CrossRef
26.
Zurück zum Zitat Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American Urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408–21.CrossRefPubMed Smith DK, Toledo L, Smith DJ, Adams MA, Rothenberg R. Attitudes and program preferences of African-American Urban young adults about pre-exposure prophylaxis (PrEP). AIDS Educ Prev. 2012;24(5):408–21.CrossRefPubMed
27.
Zurück zum Zitat Eaton LA, Driffin DD, Bauermeister J, Smith H, Conway-Washington C. Minimal awareness and stalled uptake of pre-exposure prophylaxis (PrEP) among at risk, HIV-negative, black men who have sex with men. AIDS Patient Care STDS. 2015;29:423–9.CrossRefPubMed Eaton LA, Driffin DD, Bauermeister J, Smith H, Conway-Washington C. Minimal awareness and stalled uptake of pre-exposure prophylaxis (PrEP) among at risk, HIV-negative, black men who have sex with men. AIDS Patient Care STDS. 2015;29:423–9.CrossRefPubMed
28.
Zurück zum Zitat Gengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014;36(1):70–85.CrossRefPubMed Gengiah TN, Moosa A, Naidoo A, Mansoor LE. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014;36(1):70–85.CrossRefPubMed
29.
Zurück zum Zitat Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(suppl 1):S55–60.CrossRefPubMedPubMedCentral Amico KR, Stirratt MJ. Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence. Clin Infect Dis. 2014;59(suppl 1):S55–60.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Grant RM, Anderson P, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed Grant RM, Anderson P, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMed
32.
Zurück zum Zitat Andrews CD, Yueh YL, Spreen WR, Bernard LS, Boente-Carrera M, Rodriguez K, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra4.CrossRefPubMedPubMedCentral Andrews CD, Yueh YL, Spreen WR, Bernard LS, Boente-Carrera M, Rodriguez K, et al. A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med. 2015;7(270):270ra4.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4.CrossRefPubMedPubMedCentral Andrews CD, Spreen WR, Mohri H, Moss L, Ford S, Gettie A, et al. Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science. 2014;343(6175):1151–4.CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–62.CrossRefPubMedPubMedCentral Galea JT, Kinsler JJ, Salazar X, Lee S-J, Giron M, Sayles JN, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011;22(5):256–62.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Ayala G, Makofane K, Santos G-M, Beck J, Do TD, Hebert P, et al. Access to basic HIV-related services and PrEP acceptability among men who have sex with men worldwide: barriers, facilitators, and implications for combination prevention. J Sex Transm Dis. 2013. doi:10.1155/2013/953123.PubMedPubMedCentral Ayala G, Makofane K, Santos G-M, Beck J, Do TD, Hebert P, et al. Access to basic HIV-related services and PrEP acceptability among men who have sex with men worldwide: barriers, facilitators, and implications for combination prevention. J Sex Transm Dis. 2013. doi:10.​1155/​2013/​953123.PubMedPubMedCentral
38.
Zurück zum Zitat King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav. 2014;18(9):1722–5.CrossRefPubMedPubMedCentral King HL, Keller SB, Giancola MA, Rodriguez DA, Chau JJ, Young JA, et al. Pre-exposure prophylaxis accessibility research and evaluation (PrEPARE Study). AIDS Behav. 2014;18(9):1722–5.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir immune Defic Syndr. 1999;50(1):77–83.CrossRef Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir immune Defic Syndr. 1999;50(1):77–83.CrossRef
40.
Zurück zum Zitat Grov C, Rendina HJ, Whitfield THF, Ventuneac A, Parsons JT. Changes in familiarity with and willingness to take PrEP: results from a longitudinal study of highly sexually active gay and bisexual men. LGBT Health (in press). Grov C, Rendina HJ, Whitfield THF, Ventuneac A, Parsons JT. Changes in familiarity with and willingness to take PrEP: results from a longitudinal study of highly sexually active gay and bisexual men. LGBT Health (in press).
41.
Zurück zum Zitat Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.CrossRefPubMedPubMedCentral Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. 2010;54(5):548–55.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24(11):689–91.CrossRefPubMed Barash EA, Golden M. Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS. 2010;24(11):689–91.CrossRefPubMed
43.
Zurück zum Zitat Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2013;89(3):207–11.CrossRefPubMed Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2013;89(3):207–11.CrossRefPubMed
44.
Zurück zum Zitat Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88:258–63.CrossRefPubMed Holt M, Murphy DA, Callander D, Ellard J, Rosengarten M, Kippax SC, et al. Willingness to use HIV pre-exposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect. 2012;88:258–63.CrossRefPubMed
45.
Zurück zum Zitat Mustanski B, Johnson AK, Garofalo R, Ryan D, Birkett M. Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. AIDS Behav. 2013;17(6):2173–9.CrossRefPubMedPubMedCentral Mustanski B, Johnson AK, Garofalo R, Ryan D, Birkett M. Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. AIDS Behav. 2013;17(6):2173–9.CrossRefPubMedPubMedCentral
46.
Zurück zum Zitat Grov C, Cain D, Whitfield TH, Rendina HJ, Pawson M, Ventuneac A, et al. Recruiting a US National sample of HIV-negative gay and bisexual men to complete at-home self-administered HIV/STI testing and surveys: challenges and opportunities. Sex Res Soc Policy. 2015;13:1–21.CrossRef Grov C, Cain D, Whitfield TH, Rendina HJ, Pawson M, Ventuneac A, et al. Recruiting a US National sample of HIV-negative gay and bisexual men to complete at-home self-administered HIV/STI testing and surveys: challenges and opportunities. Sex Res Soc Policy. 2015;13:1–21.CrossRef
47.
Zurück zum Zitat Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA. 2013;309(13):1397–405.CrossRefPubMedPubMedCentral Greene M, Justice AC, Lampiris HW, Valcour V. Management of human immunodeficiency virus infection in advanced age. JAMA. 2013;309(13):1397–405.CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat CDC. Diagnosis of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2007–2011. HIV Surveillance Supplemental Report. 2013;18(3). CDC. Diagnosis of HIV infection among adults aged 50 years and older in the United States and dependent areas, 2007–2011. HIV Surveillance Supplemental Report. 2013;18(3).
49.
Zurück zum Zitat Kojima N, Klausner JD, editors. Is emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis for the prevention of HIV infection safer than aspirin? Open forum infectious diseases. Oxford: Oxford University Press; 2016. Kojima N, Klausner JD, editors. Is emtricitabine-tenofovir disoproxil fumarate pre-exposure prophylaxis for the prevention of HIV infection safer than aspirin? Open forum infectious diseases. Oxford: Oxford University Press; 2016.
50.
Zurück zum Zitat Gandhi M, Glidden DV, Liu A, Horng H, Amico KR, Mulligan K, et al. Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function. 23rd annual conference on retroviruses and opportunistic infections (CROI 2016), Boston; 2016. Gandhi M, Glidden DV, Liu A, Horng H, Amico KR, Mulligan K, et al. Higher cumulative TFV/FTC levels in PrEP associated with decline in renal function. 23rd annual conference on retroviruses and opportunistic infections (CROI 2016), Boston; 2016.
51.
Zurück zum Zitat Liu A, Vittinghoff E, Anderson PL, Cohen S, Doblecki-Lewis S, Bacon O, et al. Changes in renal function associated with TDF/FTC PrEP use in the US demo project. 23rd annual conference on retroviruses and opportunistic infections (CROI 2016), Boston; 2016. Liu A, Vittinghoff E, Anderson PL, Cohen S, Doblecki-Lewis S, Bacon O, et al. Changes in renal function associated with TDF/FTC PrEP use in the US demo project. 23rd annual conference on retroviruses and opportunistic infections (CROI 2016), Boston; 2016.
52.
Zurück zum Zitat Markowitz M, Frank I, Grant R, Mayer KH, Margolis DA, Hudson KJ, et al. ÉCLAIR: Phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men. 23rd annual conference on retroviruses and opportunistic infections (CROI 2016), Boston; 2016. Markowitz M, Frank I, Grant R, Mayer KH, Margolis DA, Hudson KJ, et al. ÉCLAIR: Phase 2A safety and PK study of Cabotegravir LA in HIV-uninfected men. 23rd annual conference on retroviruses and opportunistic infections (CROI 2016), Boston; 2016.
Metadaten
Titel
Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.
verfasst von
Jeffrey T. Parsons
H. Jonathon Rendina
Thomas H. F. Whitfield
Christian Grov
Publikationsdatum
21.03.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 7/2016
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1370-5

Weitere Artikel der Ausgabe 7/2016

AIDS and Behavior 7/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.